Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?

ENNIO LUBRANO, SILVIA SCRIFFIGNANO and FABIO MASSIMO PERROTTA
The Journal of Rheumatology November 2019, 46 (11) 1428-1430; DOI: https://doi.org/10.3899/jrheum.190054
ENNIO LUBRANO
Head of Academic Rheumatology Unit and MoRhe Project;
Roles: Associate Professor of Rheumatology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ENNIO LUBRANO
  • For correspondence: enniolubrano@hotmail.com
SILVIA SCRIFFIGNANO
Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio,” Università degli Studi del Molise, Campobasso, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FABIO MASSIMO PERROTTA
Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio,” Università degli Studi del Molise, Campobasso, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for FABIO MASSIMO PERROTTA
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Psoriatic arthritis (PsA) is a multifaceted disease. Within this definition, PsA can be recognized by the identification of clinical hallmarks, and generally, rheumatologists diagnose it by the presence of typical skin lesions and articular inflammatory manifestations. This process could be a very easy task especially when some phenotypic manifestations and a detectable objective disease activity are present. Sometimes, the same disease can be very challenging when some manifestations such as pain, fatigue, or even enthesitis are predominant and associated with a less detectable disease activity.

The British physician Verna Wright (1928–1998) is considered the father of the spondyloarthropathies. His interest started with PsA, and then with his junior colleagues, he made a fundamental contribution to this spectrum of diseases1.

Over the past decade, an increased knowledge of PsA pathogenesis with the identification of various cytokines as targets to be treated has revolutionized the treatment strategy2. Therefore, the possibility of personalized medicine, with different phenotypes or biomarkers, has also been proposed3. Hence, there is a potential unmet need to redefine this condition4. In fact, we have moved from a simplistic concept of “arthritis” associated with psoriasis to a more comprehensive concept of “disease” because of the frequent association with extraarticular manifestations and comorbidities5. In 2006, Scarpa, et al proposed a new definition, contemplating PsA as a systemic disease in which, on top of skin and joints, some other characteristics such as extraarticular manifestations and comorbidities should be taken into account5. The introduction of this concept has been widely noticed, and the term psoriatic disease (PD) is synonymous with PsA. This concept should be regarded as an attempt to explain this disease in a better way. PsA and psoriasis do not always lead to a systemic condition such as PD6. Moreover, it still needs to be completely understood whether the pathophysiology of some aspects of PD, such as comorbidities, are always linked depending on the same condition or just simply a coincidence of events, or are they instead related to adverse events of the treatments (e.g., nonsteroidal antiinflammatory drugs)6. In fact, the metabolic involvement in the pathogenesis, severity, and progression of PsA remains unclear7. Therefore, the concept of PsA as a “syndrome” could be defined as a combination of symptoms and signs that together represent a disease process8. This could be a better solution to describe the phenomena that occur in some patients at different stages of the natural course of PsA. Based on etymology, the term disease, from old French desaise, means “lack, discomfort;” while the term syndrome comes from the Greek and literally means “running together.” In our opinion, the term psoriatic syndrome could better describe the phenotypic complexity of PsA. PsA diagnosis is still a clinical one, primarily based on clinical phenotype owing to the various associated features, which can include skin and joint disease. Indeed, PsA, as a syndrome, can develop into different stages of the disease, mainly beginning from a true cutaneous disease that is a dermatological condition that remains so for many years. In fact, it is usually known that only a third of the psoriasis cases develop joint involvement, presenting with some different phenotypes. Moreover, a subclinical joint involvement with synovial inflammation evaluated at imaging in patients with psoriasis but without articular symptoms is well described9. Hence, a potential stratification of predominant subsets of the joint disease, the presence of extraarticular manifestations and comorbidities, is necessary for a better treatment strategy. As a consequence of these 2 main domains (skin and joint), the management of these patients is delegated to 2 specialties and aims to achieve remission or low disease activity by treating the main clinical features. To date, the assessment of remission or low disease activity is mainly based on the activity and severity of these 2 domains and on the patient’s perception of disease activity, pain, and quality of life. No importance is placed on other potential characteristics of the disease, such as comorbidities or even extraarticular manifestations10. So why not try to recognize this as a syndrome?

The idea of this new concept of “taxonomy” is that identification of PsA as a syndrome could be useful for a more personalized medicine strategy. The condition of the potential predominant subsets could be stratified for disease activity, disease severity, and eventually, the presence of extraarticular manifestations and comorbidities. For instance, obesity could be a condition associated with late onset of psoriasis and PsA but not the presence of HLA-B27, possibly identifying a different stage of the disease11.

To understand why it might be useful to adopt the concept of PsA as a syndrome, we could compare PsA to another disease in rheumatology: systemic lupus erythematosus (SLE). SLE is a prototype of syndrome, a multiorgan disease in which it is possible to recognize different types of SLE (e.g., cutaneous, nephrological, neuropsychiatric, etc.) and in which it is important to identify the various clinical features for a better treatment strategy. In both conditions (PsA and SLE) we have to combine symptoms and signs to identify and to stratify the disease. Interestingly, the 2 conditions could share some potential biomarkers, such as LL37 and anti-LL37, which have recently been proposed as potential biomarkers of PsA12, suggesting a role in the pathogenesis of this condition. Further, the 2 conditions share pathogenetic pathways and cytokines such as interleukin (IL)-12 and IL-23, as demonstrated by the efficacy in the phase II trial of ustekinumab, a well-known treatment for psoriasis and PsA, in the treatment of SLE13.

An explanation of this new concept could be the proposal of PsA pathogenesis in which different sites of onset (skin, joint, entheses, gut) have been recognized and various cells and cytokines have been involved. Therefore, a potential sequence of events can or cannot happen (“run together”) in the same patient and among the patients with PsA14.

Even if we do agree with the concept of PD, with this new proposal we could have a pathway to follow more strategic disease management, to approach the treatment considering the target to be treated15 (Table 1), and maybe to learn what more to do about this intriguing and challenging disease.

View this table:
  • View inline
  • View popup
Table 1.

Targets to be treated for the different features of the disease and consequential potential treatment strategies.

REFERENCES

  1. 1.↵
    1. Helliwell PS
    . Verna Wright: father of the spondyloarthropathies. Ann Rheum Dis 2019;78:454–5.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Veale DJ,
    2. Fearon U
    . The pathogenesis of psoriatic arthritis. Lancet 2018;391:2273–84.
    OpenUrl
  3. 3.↵
    1. Miyagawa I,
    2. Nakayamada S,
    3. Nakano K,
    4. Kubo S,
    5. Iwata S,
    6. Miyazaki Y,
    7. et al.
    Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology 2019;58:336–44.
    OpenUrl
  4. 4.↵
    1. Helliwell P,
    2. Coates L,
    3. Chandran V,
    4. Gladman D,
    5. de Wit M,
    6. FitzGerald O,
    7. et al.
    Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 2014;66:1759–66.
    OpenUrlCrossRef
  5. 5.↵
    1. Scarpa R,
    2. Ayala F,
    3. Caporaso N,
    4. Olivieri I
    . Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210–2.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Manolis AA,
    2. Manolis TA,
    3. Melita H,
    4. Manolis AS
    . Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019;38:33–54.
    OpenUrl
  7. 7.↵
    1. Haque N,
    2. Lories RJ,
    3. de Vlam K
    . Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 2016;43:376–82.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Webster’s New World Medical Dictionary.Third ed. John Wiley & Sons; 2008.
  9. 9.↵
    1. Naredo E,
    2. Möller I,
    3. de Miguel E,
    4. Batlle-Gualda E,
    5. Acebes C,
    6. Brito E,
    7. et al;
    8. Ultrasound school of the Spanish Society of Rheumatology and Spanish ECO-Aps Group
    . High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology 2011;50:1838–48.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Coates LC,
    2. Lubrano E,
    3. Perrotta FM,
    4. Emery P,
    5. Conaghan PG,
    6. Helliwell PS
    . What should be the primary target of “treat to target” in psoriatic arthritis? J Rheumatol 2019;46:38–42.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Eder L,
    2. Abji F,
    3. Rosen CF,
    4. Chandran V,
    5. Gladman DD
    . The association of obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 2017;44:437–43.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Frasca L,
    2. Palazzo R,
    3. Chimenti MS,
    4. Alivernini S,
    5. Tolusso B,
    6. Bui L,
    7. et al.
    Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA. Front Immunol 2018;9:1936.
    OpenUrl
  13. 13.↵
    1. van Vollenhoven RF,
    2. Hahn BH,
    3. Tsokos GC,
    4. Wagner CL,
    5. Lipsky P,
    6. Touma Z,
    7. et al.
    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018;392:1330–9.
    OpenUrl
  14. 14.↵
    1. Ritchlin CT,
    2. Colbert RA,
    3. Gladman DD
    . Psoriatic arthritis. N Engl J Med 2017;376:2095–6.
    OpenUrl
  15. 15.↵
    1. Lubrano E,
    2. Perrotta FM
    . Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 2017;36:2633–5.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 11
1 Nov 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?
ENNIO LUBRANO, SILVIA SCRIFFIGNANO, FABIO MASSIMO PERROTTA
The Journal of Rheumatology Nov 2019, 46 (11) 1428-1430; DOI: 10.3899/jrheum.190054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?
ENNIO LUBRANO, SILVIA SCRIFFIGNANO, FABIO MASSIMO PERROTTA
The Journal of Rheumatology Nov 2019, 46 (11) 1428-1430; DOI: 10.3899/jrheum.190054
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • From Prediction Tools to Precision Medicine in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
  • Optimizing Care for Pregnancy in Rheumatic Diseases: Barriers and Potential Solutions
  • High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance?
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire